SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessing the safety, efficacy and pharmacokinetics of SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis

Criteria

Inclusion Criteria:

• Age: 20 - 80 years old

• Gender: Male or female

• Status: Outpatients

• Elevated Serum Creatinine

Exclusion Criteria:

• Patients suspected of malignant hypertension

• Patients with a clinically significant allergy

• Patients who have received other investigational drug Other protocol-defined inclusion/exclusion criteria may apply